As we prepare for a steep increase in #cancer incidence in LMICs, coupled with high drug costs, evidence-based, @WHO-aligned, national essential medicines lists are powerful policy tools for cancer control planning.
@TheLancetOncol@UICC
https://t.co/ZAqt6wrN5g
NATO Secretary General Jens Stoltenberg delivers remarks on the Russian invasion into Ukraine and whether NATO will consider using force https://t.co/ctSSYs5Uj8
U.S. Army soldiers in the 82nd Airborne Division in Poland will be deployed to the checkpoints at the border with Ukraine to help with a possible surge in the flow of traffic, a military source with direct knowledge told @ABC News. https://t.co/u1PugP0w2j
🆕 in @Annals_Oncology an interesting Industry Corner Perspectives discussing “Paradigms for the development of transformative medicines - lessons from the #EGFR story” by W.Pao & Y.A. Nagel @Roche#LCSM
Highly recommended to read!
https://t.co/pGFjkRfT1i
A new generation of FGFR inhibitors emerged with Erdafitinib (approved in urothelial carcinoma), Pemigatinib (approved in cholangiocarcinoma) & Futibatinib (ph3 studies).
Results of the phase I/II FIGHT-101 study of Pemigatinib in advanced malignancies 👇
https://t.co/tsg3GqiUZM
The easy trick to get positive results in a clinical trial is to make control arm underperform by substandard initial treatment or inferior treatment( sometimes repeating the same treatment) on progression. Congratulations @SimonWambeke@oncology_bg for pointing this out
After several months of scribbling these for the fellows and residents on the back of patient lists and notes, I decided to make a nicer version -Plus: does not require to understand my handwriting when reviewing #bcsm or writing notes- to share with them and @Medtwitteer
Requirements for successful drug development:
🔹Investigating fundamental biology
🔹Investigating disease biology in the context of treatment
🔹Developing new technologies
You can learn more in this Industry Corner article in @Annals_Oncology 👇
https://t.co/pmY69VCxBI
⭐️Darolutamide & Survival in Metastatic, Hormone-Sensitive Prostate Cancer @NEJM
👉Darolutamide =Potent androgen-receptor
✅Risk of death lower, by 32.5%, in darolutamide vs placebo group (HR 0.68) @ASCO#ASCOGU22@OncoAlert
.https://t.co/Kw4V2ykG5k
Hong Kong recorded another record daily high of new COVID-19 cases, as the city battles its worst outbreak since the pandemic began. https://t.co/FBPCZq2b5k
Brazil recorded the most deforestation ever in the Amazon rainforest for the month of January, according to government data on Friday, as destruction continues to worsen despite the government's recent pledges to bring it under control. https://t.co/U1pgNNHNTh